New perspective for an old antidiabetic drug: Metformin as anticancer agent

Cancer Treatment and Research

Volumn 159, Issue , 2014, Pages 355-376

  Leone, Alessandra ^a   Di Gennaro, Elena ^a   Bruzzese, Francesca ^a   Avallone, Antonio ^a   Budillon, Alfredo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

AMP activated protein kinase; Diabetes mellitus; Metformin; Phenformin; PI3K pathway

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FATTY ACID SYNTHASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PACLITAXEL; PHENFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CELL METABOLISM; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE ASSOCIATION; DRUG MECHANISM; GLUCOGENESIS; GLYCOLYSIS; HOMEOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LACTIC ACIDOSIS; LUNG CANCER; MITOCHONDRIAL RESPIRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR REPROGRAMMING; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT RESPONSE; VOMITING; ANIMAL; MOUSE; NEOPLASM; REVIEW; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; NEOPLASMS;

EID: 84892678284     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-38007-5_21     Document Type: Article

References (90)

1. Aljada A, Mousa SA (2012) Metformin and neoplasia: implications and indications. Pharmacol Ther 133:108–115
2. Baba Y, Nosho K, Shima K et al (2010) Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer 103:1025–1033
3. Baur DM, Klotsche J, Hamnvik OP et al (2011) Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 60:1363–1371
4. Bayraktar S, Hernadez-Aya LF, Lei X et al (2012) Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118:1202–1211
5. Bednar F, Simeone DM (2012) Metformin and cancer stem cells: old drug, new targets. Cancer Prev Res (Phila) 5:351–354
6. Belfiore A, Frasca F (2008) IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13:381–406
7. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF et al (2010) Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9:1092–1099
8. Ben Sahra I, Regazzetti C, Robert G et al (2011) Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71:4366–4372
9. Blagosklonny MV (2011) NCI’s provocative questions on cancer: some answers to ignite discussion. Oncotarget 2:1352–1367
10. Bonanni B, Puntoni M, Cazzaniga M et al (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30(21):2593–2600
11. Bowker SL, Majumdar SR, Veugelers P et al (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258
12. Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19:223–229
13. Brown KA, Simpson ER (2010) Obesity and breast cancer: progress to understanding the relationship. Cancer Res 70:4–7
14. Buzzai M, Jones RG, Amaravadi RK et al (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745–6752
15. Chari ST, Leibson CL, Rabe KG et al (2008) Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134:95–101
16. Chen HF, Li CY, Chen P et al (2006) Seroprevalence of hepatitis B and C in type 2 diabetic patients. J Chin Med Assoc 69:146–152
17. Chlebowski RT, Aiello E, McTiernan A (2002) Weight loss in breast cancer patient management. J Clin Oncol 20:1128–1143
18. Davila JA, Morgan RO, Shaib Y et al (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54:533–539
19. Decensi A, Puntoni M, Goodwin P et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3:1451–1461
20. Dowling RJ, Niraula S, Stambolic V et al (2012) Metformin in cancer: translational challenges. J Mol Endocrinol 48:R31–R43
21. El-Mir MY, Nogueira V, Fontaine E et al (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223–228
22. El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380
23. Evans JM, Donnelly LA, Emslie-Smith AM et al (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305
24. Galli M, Van Gool F, Rongvaux A et al (2010) The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res 70:8–11
25. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899
26. Gonzalez-Angulo AM, Meric-Bernstam F (2010) Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16:1695–1700
27. Goodwin PJ, Ennis M, Pritchard KI et al (2012) Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 30:164–171
28. Goodwin PJ, Stambolic V, Lemieux J et al (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126:215–220
29. Gwinn DM, Shackelford DB, Egan DF et al (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214–226
30. Hadad S, Iwamoto T, Jordan L et al (2011) Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783–794
31. Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13:251–262
32. Higurashi T, Takahashi H, Endo H et al (2012) Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer 12:118
33. Hirsch HA, Iliopoulos D, Tsichlis PN et al (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507–7511
34. Horman S, Vertommen D, Heath R et al (2006) Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 281:5335–5340
35. Hosono K, Endo H, Takahashi H et al (2010) Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 3:1077–1083
36. Hoyo C, Schildkraut JM, Murphy SK et al (2009) IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. Int J Cancer 125:2673–2678
37. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A et al (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083
38. Iliopoulos D, Hirsch HA, Struhl K (2011) Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71:3196–3201
39. Jalving M, Gietema JA, Lefrandt JD et al (2010) Metformin: taking away the candy for cancer? Eur J Cancer 46:2369–2380
40. Ji H, Ramsey MR, Hayes DN et al (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448:807–810
41. Jin HE, Hong SS, Choi MK et al (2009) Reduced antidiabetic effect of metformin and downregulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis. Pharm Res 26:549–559
42. Jiralerspong S, Palla SL, Giordano SH et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297–3302
43. Kalender A, Selvaraj A, Kim SY et al (2010) Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11:390–401
44. Kim JW, Tchernyshyov I, Semenza GL et al (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3:177–185
45. Kim YH, Liang H, Liu X et al (2012) AMPKalpha modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res 72:2512–2521
46. Kisfalvi K, Eibl G, Sinnett-Smith J et al (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69:6539–6545
47. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13:472–482
48. Kuhajda FP (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16:202–208
49. Landman GW, Kleefstra N, van Hateren KJ et al (2010) Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33:322–326
50. Law JH, Habibi G, Hu K et al (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238–10246
51. Long YC, Zierath JR (2006) AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116:1776–1783
52. Lu CW, Lin SC, Chen KF et al (2008) Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 283:28106–28114
53. Martin M, Marais R (2012) Metformin: a diabetes drug for cancer, or a cancer drug for diabetics? J Clin Oncol 30(21):2698–2700
54. Martin MJ, Hayward R, Viros A et al (2012) Metformin accelerates the growth of BRAFV600E-driven melanoma by upregulating VEGF-A. Cancer Discov 2:344–355
55. Massoner P, Ladurner-Rennau M, Eder IE et al (2010) Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer 103:1479–1484
56. Matsuo J, Tsukumo Y, Saito S et al (2012) Hyperactivation of 4E-binding protein 1 as a mediator of biguanide-induced cytotoxicity during glucose deprivation. Mol Cancer Ther 11:1082–1091
57. Mazzone PJ (2010) Lung cancer screening: an update, discussion, and look ahead. Curr Oncol Rep 12:226–234
58. Mazzone PJ (2010) Preoperative evaluation of the lung cancer resection candidate. Expert Rev Respir Med 4:97–113
59. Memmott RM, Mercado JR, Maier CR et al (2010) Metformin prevents tobacco carcinogen– induced lung tumorigenesis. Cancer Prev Res (Phila) 3:1066–1076
60. Monami M, Colombi C, Balzi D et al (2011) Metformin and cancer occurrence in insulintreated type 2 diabetic patients. Diabetes Care 34:129–131
61. Noto H, Goto A, Tsujimoto T et al (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7:e33411
62. Onitilo AA, Engel JM, Glurich I et al (2012) Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control 23:991–1008
63. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(Pt 3):607–614
64. Pannala R, Basu A, Petersen GM et al (2009) New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 10:88–95
65. Papandreou I, Cairns RA, Fontana L et al (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3:187–197
66. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928
67. Pollak M (2012) Metformin and pancreatic cancer: a clue requiring investigation. Clin Cancer Res 18:2723–2725
68. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437–443
69. Rocha GZ, Dias MM, Ropelle ER et al (2011) Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 17:3993–4005
70. Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010) Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16:2505–2511
71. Samudio I, Fiegl M, Andreeff M (2009) Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 69:2163–2166
72. Segal ED, Yasmeen A, Beauchamp MC et al (2011) Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem Biophys Res Commun 414:694–699
73. Seyfried TN, Shelton LM (2010) Cancer as a metabolic disease. Nutr Metab (Lond) 7:7
74. Shu Y, Sheardown SA, Brown C et al (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422–1431
75. Song CW, Lee H, Dings RP et al (2012) Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2:362
76. Stambolic V (2012). A. 2012. Chicago
77. Stambolic V, Woodgett JR, Fantus IG et al (2009) Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res Treat 114:387–389
78. Tan BX, Yao WX, Ge J et al (2011) Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 117:5103–5111
79. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033
80. Vigneri P, Frasca F, Sciacca L et al (2009) Diabetes and cancer. Endocr Relat Cancer 16:1103–1123
81. Wang HQ, Altomare DA, Skele KL et al (2005) Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24:3574–3582
82. Williams T, Brenman JE (2008) LKB1 and AMPK in cell polarity and division. Trends Cell Biol 18:193–198
83. Wingo SN, Gallardo TD, Akbay EA et al (2009) Somatic LKB1 mutations promote cervical cancer progression. PLoS ONE 4:e5137
84. Zadra G, Priolo C, Patnaik A et al (2010) New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res 16:3322–3328
85. Zakikhani M, Dowling RJ, Sonenberg N et al (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 1:369–375
86. Zhang M, Hu Z, Huang J et al (2010) A 3’-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 16:1236–1244
87. Zhao Y, Liu H, Riker AI et al (2011) Emerging metabolic targets in cancer therapy. Front Biosci 16:1844–1860
88. Zheng B, Jeong JH, Asara JM et al (2009) Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33:237–247
89. Zhou G, Myers R, Li Y et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174
90. Zhuang Y, Miskimins WK (2011) Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res 9:603–615